comparemela.com

Latest Breaking News On - Tempest therapeutics - Page 2 : comparemela.com

Tempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC Wainwright

Tempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

William-blair
Tempest-therapeutics-inc
Exchange-commission
Scotiabank
Jefferies-financial-group
Nasdaq
Tempest-therapeutics-company-profile
Maytech-global-investments
Tempest-therapeutics
Get-free-report
Tech-global-investments
Free-report

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Brisbane
Queensland
Australia
California
United-states
American
Stephen-brady
Aljanae-reynolds
Sylvia-wheeler
Exchange-commission
Society-for-immunotherapy-of-cancer
American-association-for-cancer-research

Tempest Reports Inducement Grant Under Nasdaq Listing Rule

BRISBANE, Calif., April 26, 2024 (GLOBE NEWSWIRE) Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing.

Brisbane
Queensland
Australia
California
United-states
Aljanae-reynolds
Sylvia-wheeler
Tempest-therapeutics-inc
Nasdaq
Compensation-committee
Media-contacts
Nasdaq-tpst

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

BRISBANE, Calif., April 09, 2024 Tempest Therapeutics, Inc. , a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today.

United-states
California
Brisbane
Queensland
Australia
American
Sylvia-wheeler
Sam-whiting
Aljanae-reynolds
Exchange-commission-on
American-association-for-cancer-research
Exchange-commission

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data,.

California
United-states
Brisbane
Queensland
Australia
Sylvia-wheeler
Aljanae-reynolds
Sam-whiting
Cancer-research-communications
Nasdaq
Exchange-commission-on
Securities-exchange

vimarsana © 2020. All Rights Reserved.